Skip to main
ANVS
ANVS logo

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio Inc. has positioned itself advantageously in the clinical-stage pharmaceutical sector, focusing on innovative treatments for neurodegenerative diseases, with significant pipeline products including Buntanetap, ANVS405, and ANVS301. The company's progression in clinical trials, including promising interim results for Buntanetap that could modify disease progression and the strategic alignment with the FDA for potential New Drug Applications, reflects a strong commitment to advancing its lead product towards regulatory approval. Positive findings from trials and a clear roadmap for future developments enhance the company's growth potential and may lead to increased market opportunities in the treatment of Alzheimer's and Parkinson's diseases.

Bears say

Annovis Bio Inc faces significant financing risks due to a modest cash runway, which could lead to dilutive capital-raising activities. The company's pipeline is concentrated on challenging neurodegenerative diseases like Alzheimer's and Parkinson's, raising concerns over potential trial failures due to efficacy and safety issues. Additionally, there are risks associated with the lack of FDA approval for their drug filings and the possibility of unsuccessful market launches impacted by intense competition and pricing pressures.

Annovis Bio (ANVS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.